Use of corticosteroids is not associated with repeated vertebroplasty or kyphoplasty within one year after the surgery in patients older than 50 years

Feng-Chen Kao, Yao-Chun Hsu, Chin-Hsien Wu, Chang-Bi Wang, Yuan-Kun Tu, Pao-Hsin Liu

Department of Orthopaedics, E-Da Hospital, Kaohsiung, Taiwan
School of Medicine, I-Shou University, Kaohsiung, Taiwan
Big Data Research Center and School of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan
Department of Internal Medicine, E-Da Hospital, Kaohsiung, Taiwan
Department of Nursing, Central Taiwan University of Science and Technology, Taichung, Taiwan
Department of Biomedical Engineering, I-Shou University, Kaohsiung, Taiwan

Abstract

Objective: The aim of this study was to investigate whether corticosteroid use increases the incidence of repeated vertebroplasty or kyphoplasty in patients older than 50 years.

Methods: This study enrolled data from 2,753 eligible patients from the Taiwan National Health Insurance Research Database who were exposed to systemic corticosteroids for at least 3 months during the first year preceding the first vertebroplasty or kyphoplasty. These steroid users were matched 1:1 in age, sex, and the index date of surgery with non-user controls during the enrollment period. All patients were followed for 1 year after the first vertebroplasty or kyphoplasty. The incidence of repeated vertebroplasty or kyphoplasty was compared between the steroid users and controls. A Cox proportional hazards model was developed to account for multiple confounding factors.

Results: The number of patients receiving repeated vertebroplasty or kyphoplasty was 233 (8.46%) and 205 (7.45%) in the corticosteroid and control groups, respectively. The Cox proportional hazards model revealed no association between corticosteroid use and repeated vertebroplasty or kyphoplasty.

Conclusions: Systemic corticosteroid use for longer than 3 months is not associated with repeated vertebroplasty or kyphoplasty within one year of surgery in patients older than 50 years.

Level of evidence: Level III, Therapeutic study.

© 2017 Turkish Association of Orthopaedics and Traumatology. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Vertebral compression fractures (VCFs) significantly deteriorate quality of life and increase mortality in elderly people. VCFs are estimated to affect 44 million Americans with an annual healthcare cost of 440 million dollars. The morbidities of VCFs include back pain, decreased ambulation, prolonged bed rest, decreased pulmonary function, and decreased ability to live independently. Percutaneous vertebroplasty (PVP) or kyphoplasty is effective and safe for patients with painful osteoporotic VCFs and persistent pain. Pain relief after PVP or kyphoplasty is immediate, sustained for at least 1 year, and is significantly greater than that achieved using conservative treatment. However, previous studies have reported that patients receiving PVP or kyphoplasty have a greater risk of new-onset VCFs than that of patients with prior VCFs who did not undergo either procedure. Most new adjacent VCFs occur within 3 months following PVPs or kyphoplasties and new VCFs could occur repeatedly within a few years after PVP or kyphoplasties, if the steps for prevention of VCFs are not immediate and effective. The rate of new VCF occurrence was reported to reach 50% in patients with VCFs.

Patients with symptomatic new VCFs can benefit from PVP or kyphoplasty with respect to pain relief and functional improvement. PVP cannot prevent further fracture.
further fracture while treating severe osteoporotic VCFs is crucial. Therefore, recognizing and managing the risk factors for VCFs or new VCFs is critical. Risk factors for VCFs include steroid use, prior VCFs, smoking, the female sex, and local kyphosis. Possible risk factors for new VCFs after PVP or kyphoplasty include chronic oral steroid use, osteoporosis, and the treatment level being the thoracolumbar junction.

To clarify how corticosteroid use might increase the rate of new VCFs after PVP or kyphoplasty and cause the need for repeating these procedures, we determined the incidence of and calculated the multivariate-adjusted hazard ratio for repeated PVPs or kyphoplasties in a 1-year study period after the first PVP or kyphoplasty for patients with and without exposure to corticosteroids in this population-based cohort study.

Materials and methods

Study design and data source

This was a retrospective cohort study based on an analysis of the National Health Insurance Research Database (NHIRD). The Ministry of Health and Welfare has conducted the National Health Insurance (NHI) program since 1995 to cover the healthcare of 22.9 million residents in Taiwan. More than 99% of the national population is covered by this program. In the NHIRD, diseases are coded according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Data acquisition for this study was approved by the Taiwan NHRI and the study protocol was approved by the institutional review board of E-Da Hospital.

Definition of the study cohorts and outcomes

In this study, we analyzed the NHIRD to identify study cohorts. Patients with osteoporosis receiving antiresorptive agents, such as bisphosphonate, hormone therapy, and teriparatide, who had received PVP or kyphoplasty for the first time were enrolled in this study (Fig. 1). PVP or kyphoplasty surgeries were done by either unilateral or bilateral approach. Patients exposed to systemic corticosteroid therapy for at least 3 months during the previous year before receiving PVP or kyphoplasty for the first time were enrolled in the corticosteroid group. Patients who did not receive any steroid treatment in the previous year before receiving PVP or kyphoplasty for the first time were enrolled in the control group. The index date for baseline matching and outcome observation was assigned as the date when PVP or kyphoplasty was performed for the first time. The steroid users were then matched 1:1 according to age, sex, and the index date with controls who were not exposed to any dosage of a corticosteroid during the study period. Patients aged <50 years and those who used steroids for less than 3 months were excluded from the study. All patients were followed for 1 year after the first PVP or kyphoplasty was performed. Comorbidities were classified as those existing prior to the first PVP or kyphoplasty, according to Charlson’s score. Repeated PVP or kyphoplasty was recorded in both groups and used for calculation.

Statistical analysis

Continuous variables were summarized as the mean and standard deviation, and categorical variables as the number and proportion. To determine whether corticosteroids were an independent factor predicting repeated PVP or kyphoplasty, multivariate-adjusted hazard ratios (HRs) were calculated using a Cox proportional hazards model. All data management and HR calculations were performed using the SAS system (version 9.4; SAS Institute, Cary, NC). The calculated results were expressed as a ratio along with 95% confidence intervals (CIs). P values lower than 0.05 were defined as significant in all statistical tests.

Results

Baseline characteristics of the study population

In total, we screened 28,448 patients received PVP or kyphoplasty. Among those patients, 494 cases with age younger than 50 years old and 14,757 cases with systemic corticosteroid therapy for less than 3 months were excluded. There were 4668 patients with systemic corticosteroid therapy for more than 3 months and 8529 patients without steroid therapy. After 1:1 matching in this study, 5506 patients who were eligible for the study (Fig. 1). The corticosteroid and control groups contained 2753 patients each. The study included 1714 male and 3792 female patients. The baseline characteristics and comorbidities of the 5506 patients are listed in Table 1.

Repeated PVP or kyphoplasty between the study cohorts

The number of patients receiving repeated PVP or kyphoplasty was 233 (8.46%) and 205 (7.45%) in the corticosteroid group and control group, respectively (Table 1). A Cox proportional hazards model revealed no association between corticosteroid use and repeated PVP or kyphoplasty.

The multivariate-adjusted model demonstrated that diabetes and malignant tumors were associated with an increased rate of repeated PVP or kyphoplasty (adjusted HR, 0.77; 95% CI, 0.61–0.960 and 0.39; 95% CI, 0.19–0.82; respectively; P < 0.05) (Table 2). In the unadjusted analysis, dementia, connective tissue disease, and diabetes with end organ damage were associated with repeated PVP or kyphoplasty (HR, 0.64; 95% CI, 0.43–0.95, 1.34; 95% CI, 1.03–1.75, and 0.61; 95% CI, 0.40–0.91, respectively); however, this association was nonsignificant in the multivariate-adjusted Cox proportional hazard model (Table 2). The relationships between comorbidities and repeated PVP or kyphoplasty are shown in a forest plot (Fig. 2).

Discussion

Corticosteroids can cause adverse effects after long-term use. One possible adverse effect of the usage of corticosteroids is bone mass loss, especially of the trabecular bone (the predominant bone type in the vertebrae). Bone mass loss is more pronounced in the first month after therapy and 10%–20% trabecular bone loss occurs in the first 6 months after therapy. Annual bone mass loss of 2% occurs in the subsequent years. In addition, the loss of cortical bone (at a greater proportion in long bones) occurs at a rate of 2%–3% in the first year. Subsequently, slow and continuous loss of cortical bone persists. The bone mineral density (BMD) decreases significantly after the receipt of a dose of prednisone ≥7.5 mg for 3 months. Therefore, the fracture risk is expected to increase after glucocorticoid administration for 3–6 months. In addition, a clinical study reported that the incidence of vertebral and non-vertebral fractures increases by approximately 30%–50% in patients using corticosteroids for >3 months. Furthermore, the risk of fracture for the same BMD is higher in glucocorticoid-induced osteoporosis than in postmenopausal or senile osteoporosis.

Approximately 33% of patients on glucocorticoids have fractures, mainly in the vertebrae, and only 30% of such fractures are symptomatic. A previous population database study in the United Kingdom showed that the risk of fractures, mainly vertebral fractures, significantly increased in patients using glucocorticoids. Some studies have reported that risk factors for VCFs include...
steroid use, smoking, the female sex, and older age. The effect of glucocorticoids might persist for a long time and cause further harm to the patients. In recent years, the long time usage of steroid with systemic or local epidural forms were documented to lead to increase bone fragility, rapid bone loss and fracture risk (mainly vertebral fractures). Therefore, the incidence of refracture in patients with steroids might be higher than that in patients with primary osteoporosis and could be a predictor of additional symptomatic VCFs. However, other studies have revealed the opposite outcome and found no association between subsequent fractures and steroid use. In our study, the repeated PVP or kyphoplasty rates were 8.46% and 7.45% in the corticosteroid and control groups, respectively. We found that glucocorticoid use did not affect the number of repeated PVPs or kyphoplasties required. This result may be attributable to patients older than 50 years old with osteoporosis being equally prone to vertebral refracturing. Thus, patients using steroids do not require particular attention, and focus must be placed on treating osteoporosis.

Fig. 1. Flowchart of this study.
Another concern regarding the relationship between comorbidity and vertebral fracture also remains hotly debatable. In the literature, some reported that chronic obstructive pulmonary disease, autoimmune disease, collagen vascular disease including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren’s syndrome (SS), systemic sclerosis (SSc)/mixed connective tissue disease (MCTD), polymyositis/dermatomyositis (PM/DM), and microscopic polyangiitis are related to the risk of vertebral fractures.38–41 But those results are also related to long time steroid usage. In our study, the result showed that those connective tissue disease and chronic lung disease were not associated with repeated PVP or kyphoplasty. Our study showed that diabetes and metastatic malignant tumor were associated with repeated PVP or kyphoplasty. The reason might be that patients with diabetes have more chance to get falling down especially in the hypoglycemic status42 and more chance to have bone destruction with metastatic malignant tumor especially involving vertebral bones. Moreover, our stratified analyses indicated diabetes and metastatic tumor could

Table 1

| Characteristics of the study subjects. | Non-corticosteroid | Corticosteroid | p-value |
|----------------------------------------|-------------------|---------------|---------|
| Age N = 2753                           | 748 ± 8.29        | 748 ± 8.21    | 0.9999  |
| Age group                              |                   |               |         |
| 50-59                                  | 163 (5.92)        | 155 (5.63)    | 0.8274  |
| 60-79                                  | 1816 (65.96)      | 1835 (65.65)  |         |
| >80                                    | 774 (28.11)       | 763 (27.72)   |         |
| Gender                                 |                   |               |         |
| Female                                 | 1896 (68.87)      | 1896 (68.87)  | 1.0000  |
| Male                                   | 857 (31.13)       | 857 (31.13)   |         |
| CO                                      |                   |               |         |
| 0                                      | 313 (11.37)       | 74 (2.69)     | <0.0001 |
| 1                                      | 535 (19.41)       | 243 (8.83)    |         |
| 2                                      | 561 (20.38)       | 487 (17.69)   |         |
| 2+                                     | 1344 (48.82)      | 1949 (70.8)   |         |
| Comorbidities                          |                   |               |         |
| Myocardial infarct                     | 109 (3.96)        | 138 (5.01)    | 0.0590  |
| Congestive heart failure               | 428 (15.55)       | 833 (30.26)   | <0.0001 |
| Peripheral vascular disease            | 132 (4.79)        | 219 (7.95)    | <0.0001 |
| Cerebrovascular disease                | 952 (34.58)       | 980 (35.80)   | 0.4291  |
| Dementia                               | 280 (10.17)       | 234 (8.50)    | 0.0331  |
| Chronic lung disease                   | 1248 (45.33)      | 1907 (69.27)  | <0.0001 |
| Connective tissue disease              | 124 (4.50)        | 519 (18.85)   | <0.0001 |
| Ulcer                                  | 1356 (55.79)      | 2059 (74.79)  | <0.0001 |
| Chronic liver disease                  | 948 (34.44)       | 1073 (38.98)  | <0.0001 |
| Diabetes                               | 230 (8.35)        | 250 (9.08)    | 0.3393  |
| Diabetes with end organ damage          | 112 (4.07)        | 87 (3.16)     | 0.0711  |
| Hemiplegia                             | 332 (11.73)       | 510 (18.53)   | <0.0001 |
| Tumor, leukemia, lymphoma              | 381 (13.84)       | 602 (21.87)   | <0.0001 |
| Moderate or severe liver disease        | 36 (1.31)         | 37 (1.34)     | 0.9062  |
| Malignant tumor, metastasis            | 50 (1.82)         | 173 (6.28)    | <0.0001 |
| AIDS Low                                | 205 (7.45)        | 233 (8.46)    | 0.1632  |
| AIDS High                               | 743 (26.98)       | 772 (27.72)   |         |

Table 2

| Prediction for REFRACTURE. | Crude |                | Adjusted |                |
|----------------------------|-------|----------------|----------|----------------|
| Corticosteroid vs. Non-corticosteroid | 1.14 (0.95–1.38) | 0.1628 | 1.11 (0.91–1.37) | 0.3109 |
| Comorbidities               |       |                |          |                |
| Myocardial infarct          | 0.80 (0.48–1.31) | 0.3716 | 0.85 (0.51–1.41) | 0.5352 |
| Congestive heart failure    | 0.90 (0.72–1.13) | 0.3792 | 0.92 (0.72–1.17) | 0.4987 |
| Peripheral vascular disease | 0.81 (0.53–1.24) | 0.3368 | 0.90 (0.59–1.38) | 0.6243 |
| Cerebrovascular disease     | 0.84 (0.69–1.03) | 0.0999 | 0.93 (0.75–1.15) | 0.5175 |
| Dementia                    | 0.64 (0.43–0.95) | 0.0260 | 0.67 (0.45–1.01) | 0.0535 |
| Chronic lung disease        | 1.10 (0.91–1.33) | 0.3377 | 1.11 (0.91–1.37) | 0.3053 |
| Connective tissue disease   | 1.34 (1.03–1.75) | 0.0296 | 1.26 (0.96–1.66) | 0.0980 |
| Ulcer                       | 1.11 (0.91–1.35) | 0.3053 | 1.08 (0.88–1.34) | 0.4573 |
| Chronic liver disease       | 1.11 (0.90–1.36) | 0.3457 | 1.15 (0.92–1.42) | 0.2193 |
| Diabetes                    | 0.72 (0.58–0.88) | 0.0015 | 0.77 (0.61–0.96) | 0.0206 |
| Diabetes with end organ damage | 0.61 (0.40–0.91) | 0.0171 | 0.76 (0.48–1.18) | 0.2165 |
| Hemiplegia                  | 0.57 (0.29–1.10) | 0.0952 | 0.65 (0.33–1.28) | 0.2150 |
| Moderate or severe kidney disease | 0.81 (0.61–1.08) | 0.1549 | 0.85 (0.63–1.13) | 0.2598 |
| Tumor, leukemia, lymphoma   | 0.93 (0.72–1.19) | 0.5491 | 1.04 (0.80–1.35) | 0.7886 |
| Moderate or severe liver disease | 0.64 (0.24–1.71) | 0.3700 | 0.63 (0.23–1.71) | 0.3680 |
| Malignant tumor, metastasis | 0.42 (0.21–0.85) | 0.0016 | 0.39 (0.19–0.82) | 0.0122 |
| AIDS                       |       |                |          |                |

HR: Hazard Ratio.
| Subgroup                        | Non-corticosteroid | Corticosteroid | HR (95% C.I.) | P-value |
|--------------------------------|--------------------|----------------|---------------|---------|
|                                | Event N            | Event N        |               |         |
| Age group                      |                    |                |               |         |
| 50-59                          | 6 163              | 16 155         | 2.97(1.16-7.61) | 0.0229  |
| 60-79                          | 147 1816           | 167 1835       | 1.13(0.50-1.41) | 0.2982  |
| >=80                           | 52 774             | 50 765         | 0.68(0.66-1.44) | 0.9027  |
| Gender                         |                    |                |               |         |
| Female                         | 161 1896           | 179 1896       | 1.11(0.90-1.38) | 0.3234  |
| Male                           | 44 857             | 54 857         | 1.24(0.83-1.85) | 0.2893  |
| Comorbidities                  |                    |                |               |         |
| Myocardial infarct             |                    |                |               |         |
| with                           | 9 109              | 7 138          | 0.60(0.22-1.82) | 0.3137  |
| without                        | 196 2644           | 226 2615       | 1.16(0.97-1.42) | 0.0882  |
| Congestive heart failure       |                    |                |               |         |
| with                           | 28 428             | 66 833         | 1.19(0.77-1.88) | 0.4347  |
| without                        | 177 2325           | 167 1920       | 1.16(0.94-1.44) | 0.1627  |
| Peripheral vascular disease    |                    |                |               |         |
| with                           | 8 132              | 15 219         | 1.12(0.47-2.64) | 0.7967  |
| without                        | 197 2621           | 218 2534       | 1.15(0.95-1.4)  | 0.1446  |
| Cerebrovascular disease        |                    |                |               |         |
| with                           | 63 952             | 74 980         | 1.17(0.84-1.64) | 0.3619  |
| without                        | 142 1801           | 159 1773       | 1.13(0.90-1.42) | 0.2906  |
| Dementia                       |                    |                |               |         |
| with                           | 14 280             | 12 234         | 1.03(0.47-2.22) | 0.9474  |
| without                        | 191 2473           | 221 2519       | 1.14(0.94-1.39) | 0.181   |
| Chronic lung disease           |                    |                |               |         |
| with                           | 99 1248            | 162 1907       | 1.06(0.83-1.36) | 0.6403  |
| without                        | 106 1505           | 71 846         | 1.23(0.91-1.66) | 0.1853  |
| Connective tissue disease      |                    |                |               |         |
| with                           | 9 124              | 55 519         | 1.51(0.74-3.05) | 0.2538  |
| without                        | 196 2629           | 178 2234       | 1.07(0.87-1.31) | 0.5387  |
| Ulcer                          |                    |                |               |         |
| with                           | 123 1536           | 171 2059       | 1.04(0.83-1.32) | 0.7138  |
| without                        | 82 1217            | 62 694         | 1.32(0.95-1.83) | 0.1025  |
| Chronic liver disease          |                    |                |               |         |
| with                           | 49 626             | 75 840         | 1.12(0.78-1.61) | 0.5383  |
| without                        | 156 2127           | 158 1913       | 1.14(0.91-1.42) | 0.2481  |
| Diabetes                       |                    |                |               |         |
| with                           | 60 948             | 67 1073        | 0.97(0.69-1.38) | 0.8852  |
| without                        | 145 1805           | 166 1680       | 1.25(1.00-1.56) | 0.0481  |
| Diabetes with end organ damage |                    |                |               |         |
| with                           | 12 230             | 12 250         | 0.93(0.42-2.07) | 0.8576  |
| without                        | 193 2523           | 221 2503       | 1.16(0.96-1.41) | 0.1282  |
| Hemiplegia                     |                    |                |               |         |
| with                           | 4 112              | 5 87           | 1.58(0.42-5.87) | 0.4972  |
| without                        | 201 2641           | 228 2666       | 1.13(0.94-1.37) | 0.2048  |
| Moderate or severe kidney disease |                    |                |               |         |
| with                           | 21 323             | 34 510         | 1.05(0.61-1.82) | 0.8492  |
| without                        | 184 2430           | 199 2243       | 1.17(0.96-1.43) | 0.1212  |
| Tumor, leukemia, lymphoma      |                    |                |               |         |
| with                           | 30 381             | 43 602         | 0.86(0.56-1.32) | 0.6227  |
| without                        | 175 2372           | 190 2151       | 1.21(0.99-1.49) | 0.0677  |
| Moderate or severe liver disease |                    |                |               |         |
| with                           | 2 36               | 2 37           | 0.97(0.14-5.90) | 0.97    |
| without                        | 203 2717           | 231 2716       | 1.14(0.85-1.53) | 0.1619  |
| Malignant tumor, metastasis    |                    |                |               |         |
| with                           | 4 50               | 4 173          | 0.28(0.07-1.15) | 0.0779  |
| without                        | 201 2703           | 229 2580       | 1.20(1.00-1.46) | 0.0544  |

Fig. 2. Predictable risk factors for repeated vertebroplasty of kyphoplasty.
even modify the association of steroid with repeated vertebral surgery. All in all, these findings suggested these two underlying illnesses were more detrimental whether or not the patients received steroid.

Our study has some limitations. First, we could not obtain spine images. Therefore, we could not collect information regarding preoperative spine deformities, and this may have led to bias. Second, a wide range of steroid doses was used and therefore we could not determine whether differences in steroid doses would lead to different results. The follow up time in this study is only 1 year, so the finding of the study is valid for the first year after the first PVP or kyphoplasty. Nevertheless, a stringent definition of the dose would have biased the results toward a null association instead of creating a spurious one. Finally, unmeasured confounding is possible. We could not examine the potential influence of body weight, cigarette smoking, alcohol intake, and dietary habits, which are unavailable in the NHIRD. We could not acquire direct information on these factors because those external data are strictly prohibited for privacy protection. However, the merit of our study is that no loss to follow-up occurred, particularly because traveling to the hospitals covered by NHI is convenient.

In summary, the risk of receiving repeated PVP or kyphoplasty is not associated with steroid use for longer than 3 months even after the first years in patient older than 50 years old. While treating patients who have received PVP or kyphoplasty, the focus should be on treating osteoporosis.

**Funding**

This work was supported by the Center for Database Research, E-Da Healthcare Group (CFDR-B-105-1-1).

**Acknowledgment**

This study is based on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health and managed by the National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of the Bureau of National Health Insurance, Department of Health, or National Health Research Institutes. The authors are grateful to Ms. Tsu-Shan Chen for her efficient assistance.

**References**

1. Hall SE, Criddle RA, Comito TL, Prince RL. A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int J Establ Res Coop Bet Eur Found Osteoporos Natl Osteoporos Found USA. 1999;9:508–515.
2. Sambrook P, Cooper C. Osteoporosis. Lancet (London, England). 2006;367:2010–2018.
3. Phillips FM. Minimal invasive treatments of osteoporotic vertebral compression fractures. Spine. 2003;28:545–553.
4. Johnell O, Kanis JA, Oden A, et al. Mortality after osteoporotic fractures. Osteoporos Int J Establ Res Coop Bet Eur Found Osteoporos Natl Osteoporos Found USA. 2004;15:38–42.
5. Kanis JA, Prit FA. Epidemiology of osteoporosis. Bone. 1992;13:57–515.
6. Ploeg WT, Veldhuizen AG, The B, Sietema MS. Percutaneous vertebroplasty as a treatment for osteoporotic vertebral compression fractures: a systematic review. Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deformity Soc Eur Spine Soc Eur Spine Res Soc. 2006;15:1749–1758.
7. Mudano AS, Biai J, Cope JU, et al. Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a population-based cohort study. Osteoporos Int J Establ Res Coop Bet Eur Found Osteoporos Natl Osteoporos Found USA. 2009;20:819–826.
8. Boger A, Heini P, Windolf M, Schneider E. Adjacent vertebral failure after vertebroplasty: a biomechanical study of low-modulus PMMA cement. Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deformity Soc Eur Spine Res Soc. 2007;16:2118–2125.
9. Trout AT, Kalines DF, Kaufmann TJ. New fractures after vertebroplasty: adjacent fractures occur significantly sooner. AJNR Am J Neuroradiol. 2006;27:227–232.
10. Voormolen MH, Lohe PN, Juttmann JR, van der Graaf Y, Fransen H, Lammens EM. The risk of new osteoporotic vertebral compression fractures in the year after percutaneous vertebroplasty. J Vasc Interv Radiol JVR. 2006;17:741–746.
11. Tseng YY, Yang TC, Tu PH, Lo YL, Yang ST. Repeated and multiple new vertebral compression fractures after percutaneous transpedicular vertebroplasty. Spine. 2009;34:1917–1922.
12. Leslie JT, Benfo RD. Kyphoplasty treatment of vertebral compression fractures: 2-year outcomes show sustained benefits. Spine. 2006;31:57–64.
13. Uppin AA, Hirsch JA, Centenera LV, Pfeifer BA, Pazianos AG, Choi IS. Occurrence of new vertebral body fracture after percutaneous vertebroplasty in patients with osteoporosis. Radiology. 2003;226:119–124.
14. Friibourg D, Tang C, Sra P, Delamarre R, Bae H. Incidence of subsequent vertebral fracture after kyphoplasty. Spine. 2004;29:2270–2276. discussion 2276–2277.
15. Garfin SR, Yuan HA, Reiley MA. New technologies in spine: kyphoplasty and vertebroplasty for the treatment of painful osteoporotic compression fractures. Spine. 2001;26:1511–1515.
16. Harrop JS, Pope B, Reinhardt NK, Lieberman I. Primary and secondary osteoporosis’ incidence of subsequent vertebral compression fractures after kyphoplasty. Spine. 2004;29:2120–2125.
17. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture: a meta-analysis. 2001;28:320–327.
18. Rao DE, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebroplasty incidence in women. Ann Intern Med. 1991;114:919–923.
19. Tsuchiya R, Ching AC, Byrd GD, Hiraztkha JR, Threlkeld JE, Hart R. Predictors and prevalence of patients undergoing additional kyphoplasty procedures after an initial kyphoplasty procedure. Spine J Off J North Am Spine Soc. 2010;10:979–986.
20. Lin WC, Lee YC, Lee CH, et al. Refractures in cemented vertebrae after percutaneous vertebral: a retrospective analysis. Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deformity Soc Eur Sect Cerv Spine Res Soc. 2008;17:592–599.
21. Charlson ME, Pompei P, Alex LS, MacKenzie CR. A new method of prognostic grading in longituinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
22. Pereira RM, Carvalho JF, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol. 2012;52:580–593.
23. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int J Establ Res Coop Bet Eur Found Osteoporos Natl Osteoporos Found USA. 2002;13:777–787.
24. Papiris L, Rahijevs M. [Glucocorticoid-induced osteoporosis]. J Pol Arch Wewnematr. 2007;117:363–369.
25. Kaji H, Yamauchi M, Chihara K, Sugimoto T. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis. Endocr J. 2006;53:27–34.
26. Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006;39:253–259.
27. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res Off J Am Soc Bone Miner Res. 2005;20(5):1487–1494. discussion 1486.
28. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med. 1999;159:1213–1220.
29. Donovan MA, Kandjhi AG, Siris E. Multiple adjacent vertebral fractures after kyphoplasty in a patient with steroid-induced osteoporosis. J Bone Miner Res Off J Am Soc Bone Miner Res. 2004;19:712–713.
30. Lyles KW. Management of patients with vertebral compression fractures. Pharmacotherapy. 1999;19:21a–24a.
31. Pluim SJM, Tromp AM, Smit JH, Deeg DJ, Lips P. Consequences of vertebral deformities in older men and women. J Bone Miner Res Off J Am Soc Bone Miner Res. 2000;15:1564–1572.
32. MacAulay S, Schilling J, Petersen J, Yao DS, Sanders W. A retrospective analysis of vertebral body fractures following epidural steroid injections. J Bone Jt Surg Am Vol. 2013;95:961–964.
33. Ioannidi G, Mallam S, Papadopoulos A, et al. Glucocorticoids predict 10-year fragility fracture risk in a population-based ambulatory cohort of men and women: Canadian Multicentre Osteoporosis Study (CaMoS). Arch Osteoporos. 2014;9:169.
34. Jankovic T, Sourac JZ, Boskovic K. Validation of osteoporotic vertebral fractures caused by glucocorticoids. Med Pregf. 2014;67:118–122.
35. Syd MI, Patel NA, Jan S, Shaikh A, Grunden B, Morar K. Symptomatic refractures after vertebroplasty in patients with steroid-induced osteoporosis. AJNR Am J Neuroradiol. 2006;27:1938–1943.
36. Hlawatsch A, Westermann P, Refractures with osteoporosis on steroid medication tend to sustain subsequent fractures. AJNR Am J Neuroradiol. 2007;28:1055–1057.
37. Heo DH, Chin DK, Yoon YS, Kuhn SJ. Recallopse of previous vertebral compression fracture after percutaneous vertebroplasty. Osteoporos Int J Establ
38. Migita K, Iwanaga N, Imadachi S, et al. Incidence of symptomatic vertebral fractures among newly diagnosed autoimmune diseases initiating glucocorticoid therapy. *Medicine*. 2015;94:e875.

39. Tatsuno I, Suzuki S, Yoshida T, et al. Disease-related risk of vertebral fracture during glucocorticoid treatment of collagen vascular diseases. *J Rheumatol*. 2011;38:2270–2272.

40. Sugiyama T, Suzuki S, Yoshida T, et al. Incidence of symptomatic vertebral fractures in women of childbearing age newly treated with high-dose glucocorticoid. *Gend Med*. 2010;7:218–229.

41. Majumdar SR, Villa-Roel C, Lyons KJ, Rowe BH. Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease. *Respir Med*. 2010;104:260–266.

42. Drees BM. Repeated vertebral compression fractures during hypoglycemia unawareness. *Diabet Care*. 1994;17:1076–1077.